comparemela.com

Latest Breaking News On - Scott struthers - Page 1 : comparemela.com

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

University-of-massachusetts
Massachusetts
United-states
International-center
University-of-massachusetts-medical-school
Corey-davis
Scott-struthers
Capsida-biotherapeutics
Robertm-cuddihy
Natalie-badillo
Harvard-medical-school
Exchange-commission

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical ...

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical ...
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

University-of-massachusetts
Massachusetts
United-states
University-of-massachusetts-medical-school
International-center
Robertm-cuddihy
Corey-davis
Natalie-badillo
Scott-struthers
Capsida-biotherapeutics
Securities-exchange
University-of-minnesota-medical-school

Robert W. Baird Boosts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $62.00

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target boosted by Robert W. Baird from $52.00 to $62.00 in a research note issued to investors on Thursday, Benzinga reports. They currently have an outperform rating on the stock. A number of other equities research analysts have also recently commented on CRNX. Oppenheimer raised their […]

Texas
United-states
Arizona
Stephenf-betz
Piper-sandler
Richard-scott-struthers
Robertw-baird
News-ratings-for-crinetics-pharmaceuticals-daily
Victory-capital-management-inc
Analyst-recommendations-for-crinetics-pharmaceuticals
Securities-exchange-commission
Crinetics-pharmaceuticals-stock-performance

Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $70.00 Price Target at Morgan Stanley

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Several other equities research analysts have also recently commented on CRNX. Jonestrading increased their price objective on Crinetics Pharmaceuticals […]

Arizona
United-states
Texas
Robertw-baird
Dana-pizzuti
Richard-scott-struthers
Analyst-recommendations-for-crinetics-pharmaceuticals
Cantor-fitzgerald
Principal-financial-group-inc
Securities-exchange-commission
News-ratings-for-crinetics-pharmaceuticals-daily
Morgan-stanley

Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $70.00

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Other analysts also recently issued research reports about the stock. Robert W. Baird raised their price target on shares […]

California
United-states
Stephenf-betz
Robertw-baird
Richard-scott-struthers
Janus-henderson-group
Comerica-bank
Artal-group
Analyst-recommendations-for-crinetics-pharmaceuticals
Insider-activity-at-crinetics-pharmaceuticals
Securities-exchange-commission
Investment-company-inc

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.